Chlorotoxin-Based CAR T-Cell Therapy Demonstrates Safety and Feasibility in Recurrent Glioblastoma Phase 1 Trial
核心洞察
A phase 1 trial of chlorotoxin-directed CAR T-cell therapy showed no deleterious reactions and was well-tolerated in 4 patients with recurrent glioblastoma (搜索).
The novel therapy, incorporating a peptide derived from scorpion venom, demonstrated biological activity with visible signs on MRIs and cytokine production indicating CAR T-cell activation in tumors.
While responses were not as strong as anticipated, the study successfully met its primary objectives of establishing safety and feasibility for this innovative cellular therapy approach.
A novel CAR T-cell therapy incorporating chlorotoxin, a peptide derived from scorpion venom, has demonstrated safety and feasibility in treating patients with recurrent glioblastoma (搜索), according to interim results from a phase 1 clinical trial. The study, conducted at City of Hope (搜索), enrolled 4 patients with recurrent glioblastoma and showed no deleterious reactions while providing evidence of biological activity.
Safety Profile and Clinical Activity
Michael Barish, PhD, chair in the Department of Neurosciences/Developmental & Stem Cell Biology at City of Hope (搜索), reported that the chlorotoxin-directed CAR T-cell therapy was well-tolerated across all treated patients. "We were very pleased that, in fact, we had essentially no deleterious reactions in the patients whom we gave it to," Barish stated.
The therapy demonstrated biological activity through multiple indicators. MRI scans revealed signs of biological activity in some cases, and cytokine production was observed, indicating that the CAR T cells were active within the tumor environment. "You could see cytokine production, indicating that the CAR T cell was active in the tumor; that was the most important thing," Barish explained.
Patients responded when the therapy was injected into the tumor cavity following surgical resection, confirming the treatment's biological activity. While the responses were not as robust as hoped, Barish emphasized that the primary objectives of the phase 1 trial were met: "A phase 1 trial is to show safety and feasibility, and we did see that."
Mechanistic Advantages
The chlorotoxin-based approach offers distinct mechanistic advantages over other cellular therapies for glioblastoma (搜索) treatment. According to Barish, the therapy can bind to more glioblastoma cells within a tumor compared to other recognition elements that could be incorporated into engineered T cells. This is particularly important given the heterogeneous nature of glioblastoma tumors.
"It does not bind with great affinity, but it binds with good avidity, meaning that it's extremely specific for the glioblastoma (搜索) cells as compared to any other cells in the body," Barish noted. This specificity is crucial for avoiding on-target, off-tumor effects, which could cause significant adverse reactions.
The research builds on previous knowledge that chlorotoxin is safe when administered to humans, though it had never been used in this particular therapeutic application. Other research groups have explored chlorotoxin for fluorescent tagging to create "tumor paint" that helps surgeons identify glioblastoma (搜索) cells during surgery.
Research Collaboration and Development
The study emerged from a collaboration between Barish and Christine Brown, PhD, deputy director of the T Cell Therapeutics Research Laboratory and professor in the Departments of Hematology & Hematopoietic Cell Transplantation and Immuno-Oncology at City of Hope (搜索). Barish, a neurobiologist by training, conceived the idea of using the toxin in this novel way.
"We were quite prepared for it to be one of those bright ideas that does not pan out...but the fact that it went to a clinical trial was quite surprising to us," Barish reflected on the unexpected progression from concept to clinical testing.
The phase 1 trial (NCT04214392) represents an important step in developing new treatment options for recurrent glioblastoma (搜索), a challenging cancer with limited therapeutic alternatives. The successful demonstration of safety and feasibility provides a foundation for potential future studies to optimize the therapy's efficacy.